Treatment of resectable gastric cancer: current standards of care

References

• Stewart BW, Kleihues P. (Eds). World Cancer Report. IARC Press, Lyon, France (2003).
   Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Haenszel W. Variation in incidence of and mortality from stomach cancer, with particular reference to the United States. J. Natl Cancer Inst.21, 213–262 (1958).
   PubMedGoogle Scholar
• Hirayama T. Epidemiology of cancer of the stomach with special reference to its recent decrease in Japan. Cancer Res.35, 3460–3463 (1975).
   PubMedGoogle Scholar
• Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur. J. Cancer39, 1603–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Barker DJ, Coggon D, Osmond C, Wickham C. Poor housing in childhood and high rates of stomach cancer in England and Wales. Br. J. Cancer61, 575–578 (1990).
   PubMed Web of Science ®Google Scholar
• Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin. Oncol.23, 281–291 (1996).
   PubMed Web of Science ®Google Scholar
• Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch. Intern. Med.150, 2022–2026 (1990).
   PubMedGoogle Scholar
• Shin WS, Kang MW, Kang JH et al. Epstein–Barr virus-associated gastric adenocarcinomas among Koreans. Am. J. Clin. Pathol.105, 174–181 (1996).
   PubMed Web of Science ®Google Scholar
• Bulay O, Mirvish SS, Garcia H et al. Carcinogenicity test of six nitrosamides and a nitrosocyanamide administered orally to rats. J. Natl Cancer Inst.62, 1523–1528 (1979).
   PubMedGoogle Scholar
• Shikata K, Kiyohara Y, Kubo M et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int. J. Cancer119, 196–201 (2006).
   PubMed Web of Science ®Google Scholar
• Hoskins LC, Loux HA, Britten A, Zamcheck N. Distribution of ABO blood groups in patients with pernicious anemia, gastric carcinoma and gastric carcinoma associated with pernicious anemia. N. Engl. J. Med.273, 633–637 (1965).
   Google Scholar
• Gayther SA, Gorringe KL, Ramus SJ et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res.58, 4086–4089 (1998).
   PubMed Web of Science ®Google Scholar
• Hsing AW, Hansson LE, McLaughlin JK et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer71, 745–750 (1993).
   PubMed Web of Science ®Google Scholar
• Mizoue T, Yoshimura T, Tokui N et al. Prospective study of screening for stomach cancer in Japan. Int. J. Cancer106, 103–107 (2003).
   PubMedGoogle Scholar
• Llorens P. Gastric cancer mass survey in Chile. Semin. Surg. Oncol.7, 339–343 (1991).
   PubMedGoogle Scholar
• Pisani P, Oliver WE, Parkin DM, Alvarez N, Vivas J. Case–control study of gastric cancer screening in Venezuela. Br. J. Cancer69, 1102–1105 (1994).
   PubMedGoogle Scholar
• Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann. Surg.232, 362–371 (2000).
   PubMed Web of Science ®Google Scholar
• Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer107(9), 2143–2151 (2006).
   PubMed Web of Science ®Google Scholar
• Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet347, 995–999 (1996).
   PubMed Web of Science ®Google Scholar
• Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer79, 1522–1530 (1999).
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph node dissection for gastric cancer. N. Engl. J. Med.340, 908–914 (1999).
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol.22, 2069–2077 (2004).
   PubMed Web of Science ®Google Scholar
• Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur. J. Surg. Oncol.30(3), 303–308 (2004).
   PubMed Web of Science ®Google Scholar
• Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan Clinical Oncology Group Study 9501. J. Clin. Oncol.22, 2767–2773 (2004).
   PubMed Web of Science ®Google Scholar
• Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med.359(5), 448–451 (2008).
   Google Scholar
• Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology7(4), 279–280 (2006).
   Google Scholar
• Earle CC, Maroun, JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer35, 1059–1064 (1999).
   PubMed Web of Science ®Google Scholar
• Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann. Oncol.11, 837–843 (2000).
   PubMed Web of Science ®Google Scholar
• Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of published literature for survival endpoints. Stat. Med.17, 2815–2834 (1998).
   PubMed Web of Science ®Google Scholar
• Buyse M, Piedbois P. On the relationship between reponse to treatment and survival time. Stat. Med.15(24), 2797–2812 (1996).
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med.357(18), 1810–1820 (2007).
   PubMed Web of Science ®Google Scholar
• Chang H, Kang, Y et al. A randomized Phase III trial comparing mitomycin C plus short term doxifluridine (MF) versus mitomycin C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer AMC 0201. J. Clin. Oncol.26, 4531 (2008).
   Google Scholar
• Kang Y, Chang H et al. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: a randomized Phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin C plus short-term doxifluridine (MF) AMC 0101. J. Clin. Oncol.26, 4511 (2008).
   Google Scholar
• Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br. J. Cancer60, 739–744 (1989).
   PubMed Web of Science ®Google Scholar
• Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer; five-year follow-up. Lancet343, 1309–1312 (1994).
   PubMed Web of Science ®Google Scholar
• Zhang ZX, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) – report on 370 patients. Int. J. Radiat. Oncol. Biol. Phys.42(5), 929–934 (1998).
   PubMed Web of Science ®Google Scholar
• Fiorica F, Cartei F, Enea M et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat. Rev.33, 729–740 (2007).
   Google Scholar
• MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med.345, 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med.355, 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus: FNLCC ACCORD07-FFCD 9703 trial. J. Clin. Oncol.25, 200 (2007).
   Google Scholar
• Ajani JA, Winter K, Okawara GS et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J. Clin. Oncol.24, 3953–3958 (2006).
   PubMed Web of Science ®Google Scholar